The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... and rashes to form on the skin. These lesions are prone to infection as they ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Bullous pemphigoid is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions.

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S ... reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS, Feb. 18, 2025 (GLOBE NEWSWIRE ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

It is characterized by intense itch and blisters, reddening of the skin, and painful lesions. The blisters ... chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus.